MedStar Health Research Institute
Welcome,         Profile    Billing    Logout  
 59 Trials 
147 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moriarty, Terry
NCT05046158: Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care

Recruiting
N/A
200
US
Transforming Powder Dressing, Altrazeal, Standard of care topical wound agents and dressings
ULURU Inc., Naval Medical Research Center, Military Technology Enterprise Consortium (US)
Diabetic Foot Ulcer
12/23
12/23
Ghazi, Adline
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed
3
730
Europe, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar
Eli Lilly and Company, Eli Lilly and Company
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
02/24
02/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight and Obesity
02/29
02/29
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
06/25
06/25
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)

Recruiting
N/A
240
US
EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham
GI Dynamics, Biostatistical Consulting, Inc.
Diabetes type2, Obesity
04/24
04/25
Park, Jean
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight and Obesity
02/29
02/29
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
09/25
09/27
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
NCT05343065: A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B

Completed
N/A
27
US
BlueStar 10
Welldoc
Diabetes Mellitus
12/22
12/22
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)

Recruiting
N/A
240
US
EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham
GI Dynamics, Biostatistical Consulting, Inc.
Diabetes type2, Obesity
04/24
04/25
NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

Recruiting
N/A
575
US
MiniMed™ 780G Insulin Pump system
Medtronic Diabetes
Type 2 Diabetes Treated With Insulin
10/24
02/25
Moriarty, Theresa
TIPI, NCT04453293: Immunization With BCG Vaccine to Prevent Tuberculosis Infection

Recruiting
3
2000
US
BCG (Tokyo 172) vaccine, Placebo, sodium glutamate
Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences
Tuberculosis Infection
09/27
09/27
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Active, not recruiting
2/3
125
Canada, US
LAU-7b, fenretinide, Placebo oral capsule
Laurent Pharmaceuticals Inc.
COVID-19 Disease
02/24
05/24
SAFE KIDNEY II, NCT05769582: Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients

Recruiting
2/3
180
US
Anti-BK polyomavirus (AntiBKV)
Memo Therapeutics AG
BK Viremia; BKV DNAemia
11/24
11/24
APT.DFO.001, NCT05177107: Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

Recruiting
2b
126
US
Phage Therapy, Placebo
Adaptive Phage Therapeutics, Inc., United States Department of Defense
Osteomyelitis, Diabetic Foot Osteomyelitis
04/24
12/24
SEPSIS-SHIELD, NCT04094818: HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis

Recruiting
N/A
1500
Europe, US
HostDx Sepsis
Inflammatix
Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Sepsis
05/24
05/24
NCT05176899: Real-World Evaluation of Eko Murmur Analysis Software in a Point of Care Setting

Recruiting
N/A
1200
US
Use of Eko CORE electronic stethoscope
Eko Devices, Inc.
Murmur, Heart, Innocent Murmurs, Heart Murmurs, Pathologic Murmur
11/23
11/23
NCT05046158: Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care

Recruiting
N/A
200
US
Transforming Powder Dressing, Altrazeal, Standard of care topical wound agents and dressings
ULURU Inc., Naval Medical Research Center, Military Technology Enterprise Consortium (US)
Diabetic Foot Ulcer
12/23
12/23
ICC, Washington DC
NCT05822583: Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

Recruiting
4
1500
Europe, US, RoW
abatacept infusion, Placebo group
University of Minnesota
COVID-19
07/25
07/25
INSIGHT12, NCT04910269: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/24
08/24
NCT05605093: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Recruiting
3
1500
Europe, Japan, US, RoW
Shionogi Protease Inhibitor (S-217622), ensitrelvir, placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
07/25
07/25
ICC, Washintgon
INSIGHT12, NCT04910269: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/24
08/24
Kimbiris, George
PE-TRACT, NCT05591118: Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

Recruiting
3
500
US
Anticoagulant Therapy, Catheter-Directed Therapy
NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Embolism
01/27
01/28
C-TRACT, NCT03250247: Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The Trial)

Recruiting
N/A
250
US
Stents
Washington University School of Medicine, Ontario Clinical Oncology Group (OCOG), Massachusetts General Hospital, St. Luke's Hospital, Kansas City, Missouri
Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome
01/26
04/26
Rao, Sriram
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
06/24
12/30
Bevara, Mounica
NCT04877756: Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery

Completed
2
22
US
OLX10010, a cell penetrating asymmetric small interference RNA (cp-asiRNA), targeting a gene involved in formation of fibrosis
Olix Pharmaceuticals, Inc., Alira Health
Hypertrophic Scar
01/23
07/23
Matar, Noor
VISTAS, NCT04663308: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
PAREMA1, NCT05546385: PArtial REbreathing for Migraine With Aura 1

Recruiting
N/A
175
Europe, US
Partial Rebreathing Device, Sham breathing device
Rehaler, Qmed Consulting A/S
Migraine With Aura
10/24
10/25
Brebbia, John
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)

Recruiting
N/A
240
US
EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham
GI Dynamics, Biostatistical Consulting, Inc.
Diabetes type2, Obesity
04/24
04/25
Ansari, Nasrin
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)

Recruiting
N/A
240
US
EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham
GI Dynamics, Biostatistical Consulting, Inc.
Diabetes type2, Obesity
04/24
04/25
Green, Kendra
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)

Recruiting
N/A
240
US
EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham
GI Dynamics, Biostatistical Consulting, Inc.
Diabetes type2, Obesity
04/24
04/25
FORWARD PAD, NCT05858905: IDE Study With the Shockwave Mini S IVL Catheter

Active, not recruiting
N/A
75
US
Intravascular Lithotripsy
Shockwave Medical, Inc.
Peripheral Arterial Disease
04/24
04/25
Crook, Jody
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Recruiting
N/A
958
Canada, US
Tendyne Mitral Valve System, MitraClip System
Abbott Medical Devices
Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
06/24
06/28
Vaidya, Ajay
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
06/24
12/30
Curl, Megan
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
06/24
12/30
FROST-HF, NCT05136820: Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study

Active, not recruiting
N/A
698
US
Atrial Flow Regulator, AFR, Sham Comparator
Occlutech International AB
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)
02/26
02/29
Mahoney, Kate
STAR-T, NCT04976530: Safe and Timely Antithrombotic Removal - Ticagrelor

Completed
N/A
140
Canada, US
DrugSorb-ATR system, Sorbent hemoperfusion system, Sham comparator
CytoSorbents, Inc
Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
08/23
08/23
NCT05280093: HEAL-IST IDE Trial

Recruiting
N/A
142
Europe, US
AtriCure ISOLATOR Synergy Surgical Ablation System
AtriCure, Inc.
Inappropriate Sinus Tachycardia
06/26
06/27
LeAAPS, NCT05478304: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Recruiting
N/A
6500
Europe, Canada, US
AtriClip LAA Exclusion System
AtriCure, Inc., Population Health Research Institute
Ischemic Stroke, Systemic Embolism
12/31
04/32
Pinilla-Vera, Miguel
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
06/24
12/30
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

Recruiting
N/A
300
Europe, US
Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication
Cardiac Dimensions, Inc.
Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases
12/26
12/30
Merrill, Emma
RISE 3, NCT06309966: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting
2/3
390
US
BHV-7000, Placebo
Biohaven Therapeutics Ltd.
Focal Epilepsy
08/25
09/25
 

Download Options